Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Neuca S.a. (NEU.WA)
Torun, PL
NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distribution, the development and marketing of proprietary drug brands, and a comprehensive healthcare services division. This healthcare arm specifically encompasses outpatient care, clinical trials, and telemedicine. Beyond these core areas, NEUCA S.A. provides an extensive array of additional services, including marketing and advertising support, agency functions, financial solutions, logistics through road cargo transport, accounting and bookkeeping, software development, information technology support, and specialized services for hospitals. The company also offers various insurance products—covering health, property, and other personal lines—and operates its own network of medical supply stores. Established in 1990 as Torfarm SA, the company rebranded to NEUCA S.A. in April 2010.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.78% | +6.15% | +4.83% | -0.26% | -6.30% | -9.10% | +7.36% | +9.05% | -0.91% | +126.57% | +1,656.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+8.2% ★ Q1'26: +5.7% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+0.1% Q1'26: +39.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+2.4% Q1'26: -1.2% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+1.7% Q1'26: +2.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+9.1% ★ Q1'26: +14.5% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.8% Q1'26: +1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.37× Q1'26: 1.75× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.95B
est: 7.05B (-1.5%)
|
7.08B
est: 6.95B (+1.8%)
|
7.49B
est: 7.57B (-1.1%)
|
7.75B
est: 7.75B (+0.0%)
|
8.28B
est: 8.19B (+1.1%)
|
9.25B
est: 9.17B (+0.9%)
|
9.86B
est: 9.91B (-0.4%)
|
11.23B
est: 11.28B (-0.4%)
|
11.81B
est: 12.13B (-2.6%)
|
12.61B
est: 12.82B (-1.6%)
|
13.64B
est: 13.43B (+1.6%)
|
14.31B
14.16B – 14.45B
+6.5% YoY
|
15.12B
14.82B – 15.41B
+5.7% YoY
|
15.88B
15.79B – 15.98B
+5.0% YoY
|
17.19B
17.01B – 17.36B
+8.2% YoY
|
| EBITDA |
142.92M
est: 222.52M (-35.8%)
|
182.47M
est: 219.54M (-16.9%)
|
167.14M
est: 238.84M (-30.0%)
|
190.32M
est: 244.71M (-22.2%)
|
223.61M
est: 258.55M (-13.5%)
|
273.79M
est: 289.48M (-5.4%)
|
293.42M
est: 312.77M (-6.2%)
|
352.41M
est: 355.97M (-1.0%)
|
401.82M
est: 375.10M (+7.1%)
|
417.85M
est: 396.65M (+5.3%)
|
360.38M
est: 415.48M (-13.3%)
|
442.61M
438.08M – 446.90M
+6.5% YoY
|
467.84M
458.44M – 476.75M
+5.7% YoY
|
491.39M
488.35M – 494.43M
+5.0% YoY
|
531.74M
526.31M – 536.90M
+8.2% YoY
|
| EBIT |
133.22M
est: 162.36M (-17.9%)
|
152.44M
est: 160.19M (-4.8%)
|
134.80M
est: 174.28M (-22.7%)
|
142.60M
est: 178.55M (-20.1%)
|
169.07M
est: 188.65M (-10.4%)
|
210.33M
est: 211.22M (-0.4%)
|
214.92M
est: 228.22M (-5.8%)
|
255.50M
est: 259.74M (-1.6%)
|
288.13M
est: 265.71M (+8.4%)
|
297.70M
est: 280.97M (+6.0%)
|
233.57M
est: 294.31M (-20.6%)
|
313.53M
310.32M – 316.57M
+6.5% YoY
|
331.40M
324.75M – 337.71M
+5.7% YoY
|
348.09M
345.93M – 350.24M
+5.0% YoY
|
376.67M
372.82M – 380.33M
+8.2% YoY
|
| Net Income |
101.28M
est: 95.72M (+5.8%)
|
111.73M
est: 98.46M (+13.5%)
|
94.50M
est: 88.94M (+6.2%)
|
98.27M
est: 94.58M (+3.9%)
|
117.66M
est: 116.46M (+1.0%)
|
141.79M
est: 157.64M (-10.1%)
|
150.66M
est: 177.41M (-15.1%)
|
137.24M
est: 153.12M (-10.4%)
|
146.27M
|
154.24M
est: 313.82M (-50.8%)
|
155.58M
est: 198.75M (-21.7%)
|
217.81M
209.13M – 226.50M
+9.6% YoY
|
250.80M
240.86M – 274.16M
+15.1% YoY
|
281.84M
278.18M – 285.49M
+12.4% YoY
|
520.93M
514.00M – 527.50M
+84.8% YoY
|
| SGA |
536.52M
est: 604.86M (-11.3%)
|
549.80M
est: 596.76M (-7.9%)
|
595.78M
est: 649.24M (-8.2%)
|
640.49M
est: 665.17M (-3.7%)
|
649.74M
est: 702.80M (-7.6%)
|
730.10M
est: 786.88M (-7.2%)
|
770.70M
est: 850.19M (-9.3%)
|
1.01B
est: 967.62M (+4.6%)
|
1.06B
est: 1.08B (-2.1%)
|
1.17B
est: 1.14B (+2.3%)
|
1.29B
est: 1.20B (+8.2%)
|
1.27B
1.26B – 1.29B
+6.5% YoY
|
1.35B
1.32B – 1.37B
+5.7% YoY
|
1.41B
1.40B – 1.42B
+5.0% YoY
|
1.53B
1.51B – 1.54B
+8.2% YoY
|
| EPS |
22.83
est: 21.11 (+8.2%)
|
25.35
est: 21.71 (+16.8%)
|
20.77
est: 19.61 (+5.9%)
|
19.34
est: 20.86 (-7.3%)
|
27.16
est: 25.68 (+5.8%)
|
32.81
est: 34.76 (-5.6%)
|
34.32
est: 39.12 (-12.3%)
|
31.48
est: 33.80 (-6.9%)
|
33.30
|
34.54
est: 68.70 (-49.7%)
|
34.28
est: 43.51 (-21.2%)
|
47.67
45.76 – 49.57
+9.6% YoY
|
56.35
52.71 – 60.00
+18.2% YoY
|
61.70
60.88 – 62.48
+9.5% YoY
|
114.00
112.48 – 115.44
+84.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.01% | 63.6K | 0.41% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 67.5K | 0.65% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 34.9K | 0.44% |
| 4 | iShares International Dividend Growth ETF IGRO | 0.00% | 52.4K | 0.15% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 11.4K | 0.56% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 250.6K | 0.39% |
| 7 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 13.4K | 0.07% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 165.1K | 0.28% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 25.4K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Grzegorz Dzik | President of the Management Board | 2M | male |
| Krzysztof Miszewski | Vice President of Management Board for Operations | 2M | male |
| Julita Czyzewska | Vice President of the Management Board for the Patient Area | 1M | female |
| Daniel Wojtkiewicz | Vice President of the Management Board & Director of the Sales Division | 1M | male |
| Roman Dudzik | Vice President of the Management Board the Board of Directors for the IT Division | 1M | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NEU.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
